Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: B06AC02

Firazyr(icatibant)

Angioedemas, Hereditary

Marketing Authorisation Holder: Takeda Pharmaceuticals International AG

EMA Authorisation: 11/07/2008

INN: icatibant

Indication

Firazyr is indicated for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults (with C1-esterase-inhibitor deficiency).

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Firazyr — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.